Abstract:Butyrylcholinesterase (BChE) has been considered as a potential therapeutic target for Alzheimer's disease (AD) because of its compensation capacity to hydrolyze acetylcholine (ACh) and its close association with Aβ deposit. Here, we identified S06-1011 (hBChE IC50 = 16 nM) and S06-1031 (hBChE IC50 = 25 nM) as highly effective and selective BChE inhibitors, which were proved to be safe and long-acting. Candidate compounds exhibited neuroprotective effects and the ability to improve cognition in scopolamine- and Aβ1–42 peptide-induced cognitive deficit models. The best candidate S06-1011 increased the level of ghrelin, a substrate of BChE, which can function as improving the mental mood appetite. The weight gain of the S06-1011-treated group remarkably increased. Hence, BChE inhibition not only plays a protective role against dementia but also exerts a great effect on treating and nursing care.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00167?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00167</a>.Molecular dynamics—8012-9656 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_001.pdb">PDB</a>)Molecular dynamics—S06-1002 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_002.pdb">PDB</a>)Molecular dynamics—S06-1011 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_003.pdb">PDB</a>)Molecular dynamics—S06-1014 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_004.pdb">PDB</a>)Molecular string formulas (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_005.csv">CSV</a>)Compound characterization; inhibitory rates on eeAChE and on eqBChE of partial compounds; molecular docking modes of S06-1002, S06-1011, and S06-1014; molecular dynamic simulation results of S06-1001, S06-1002, S06-1011, and S06-1014; chromatographic and mass spectrometric identification information for S06-1011; standard curves for pharmacokinetics and PAMPA study; quantization of ROS production; protocol for the in vivo experiments (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_006.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of 4-Benzylpiperazinequinoline BChE Inhibitor That Suppresses Neuroinflammation for the Treatment of Alzheimer's Disease

Discovery, Structure-Based Modification, In Vitro , In Vivo , and In Silico Exploration of m -Sulfamoyl Benzoamide Derivatives as Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer’s Disease

Discovery, Structure-Based Modification, in Vitro, in Vivo, and in Silico Exploration of M-Sulfamoyl Benzoamide Derivatives As Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer's Disease.

Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

N-Benzyl Benzamide Derivatives As Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease

Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement

Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer's disease

Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor

Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation

Design, synthesis and biological evaluation of novel pyrazolone derivatives as selective butyrylcholinesterase inhibitors with antioxidant activity against Alzheimer's disease

Development of the “hidden” multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer's disease

Design, Synthesis, In Vitro And In Vivo Evaluation Of Benzylpiperidine-Linked 1,3-Dimethylbenzimidazolinones As Cholinesterase Inhibitors Against Alzheimer'S Disease

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease

Novel and Potent Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease from Natural ()-7,8-Dihydroxy-3-methyl-isochroman-4-one

Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine

Optimizing Drug-Like Properties of Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement: Enhancing Aqueous Solubility by Disrupting Molecular Plane

Discovery and Biological Evaluation of New Selective Acetylcholinesterase Inhibitors with Anti-Aβ Aggregation Activity Through Molecular Docking-Based Virtual Screening.

Design, Synthesis, Biological Evaluation and Molecular Modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] Dioxole-5-carboxamides As Selective Butyrylcholinesterase Inhibitors.